Cost‐effectiveness analysis of Dexcom <scp>ONE</scp> + real‐time continuous glucose monitoring versus self‐monitoring of blood glucose in people with type 2 diabetes in Aotearoa New Zealand

This analysis provides insight into the cost-effectiveness of rt-CGM versus SMBG from the perspective of payers in New Zealand, demonstrating reductions in the risks of complications in addition to reductions in their associated costs.